Recent Updates
Recently added Catalysts
NAGE Positive Sentiment

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thursday, September 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Niagen Bioscience, Inc. has announced the engagement of Red Sky Partners to assist in the development of its investigational drug candidate, NB4168. This collaboration aims to advance the drug targeting rare genetic diseases and aging-related disorders. The involvement of veteran pharmaceutical executives is expected to enhance the company's strategic growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Engagement of experienced pharmaceutical executives.
  • Focus on advancing a drug candidate for rare diseases.
  • Strategic partnership with a reputable advisory firm.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders. The Compan

Frequently Asked Questions

What is NB4168?

NB4168 is Niagen Bioscience's investigational drug candidate targeting rare genetic diseases.

Who is supporting Niagen's drug development?

Niagen has engaged Red Sky Partners for strategic advisory support in drug development.

What is the focus of Niagen Bioscience?

Niagen focuses on NAD+ and the science of healthy aging.

What type of diseases does NB4168 target?

NB4168 targets rare genetic diseases and aging-related disorders.

ShareAdd on Google
Tags: NAGE Viatris Investor Conferences Healthcare NAD+ NB4168 rare diseases aging disorders
Last updated: Sep 17, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
Low dilution risk
Lead asset
NiagenPlusPhase 1
Healthy Volunteer →